Source: Annual Congress 2010 - Tuberculosis and HIV coinfection
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. K. Ong, W. C. Tan, W. L. Chung, A. R. Muttalif, R. L. C. Loh (Georgetown, Malaysia). How soon does tuberculosis in HIV infected patients respond to anti-tuberculous treatment?. Eur Respir J 2010; 36: Suppl. 54, 3864

Member's Comments

No comment yet.

Related content which might interest you: Has the time come to shorten TB treatment and TB preventive therapy? Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Does chemotherapy reactivate SARS-CoV-2 in cancer patients recovered from prior COVID-19 infection? Source: Eur Respir J, 56 (4) 2002672; 10.1183/13993003.02672-2020 Year: 2020 On abandon of the tuberculosis treatment Source: Eur Respir J 2003; 22: Suppl. 45, 522s Year: 2003 Directly observed therapy versus self administered therapy for patients of new smear positive pulmonary tuberculosis during hospitalisation period Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population Source: Eur Respir J 2005; 26: Suppl. 49, 624s Year: 2005 A choice of regimen improves completion for patients with latent TB infection Source: Breathe 2008; 4: 366 Year: 2008 Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019 Resistance to second-line antituberculous drugs of Mtb strains in TB institute clinic Source: Eur Respir J 2007; 30: Suppl. 51, 442s Year: 2007 Should tuberculosis treatment and control be addressed differently in HIV-infected and -uninfected individuals? Source: Eur Respir J 2005; 25: 751-757 Year: 2005 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Effectiveness of intravenous isoniazid and ethambutol administration in patients with new smear positive drug-susceptible pulmonary tuberculosis with tuberculous meningoencephalitis and HIV co-infection in the intensive phase of treatment Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Immunologic recovery in HIV/TB co-infected patients after anti-TB treatment Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis? Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 Treatment of migrants with tuberculosis in an era of emerging drug resistance Source: Annual Congress 2010 - Tuberculosis drug resistance and migration Year: 2010 Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is “blind” treatment dangerous? Source: Eur Respir J 2011; 37: 1283-1285 Year: 2011 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1594-1595 Year: 2016